Conmed (CNMD) Tops Q4 EPS by 4c, Beats on Revenues; Offers FY18 EPS Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
CONMED (CNMD) PT Raised to $54 at Piper Jaffray
February 1, 2018 6:41 AM ESTPiper Jaffray raised its price target on CONMED (NASDAQ: CNMD) to $54.00 (from $46.00) while maintaining a Neutral rating.
... MoreCONMED (CNMD) PT Raised to $71 at Needham & Company
February 1, 2018 6:22 AM ESTNeedham & Company raised its price target on CONMED (NASDAQ: CNMD) to $71.00 (from $58.00) while maintaining a Buy rating.
Analyst Mike Matson commented, "CNMD's 4Q17 revenue and EPS beat consensus and management guided to above-consensus 2018 revenue and EPS. Its revenue growth improved to... More
